CD55 and CD59 are
complement regulatory
proteins that are linked to the cell membrane via a
glycosyl-phosphatidylinositol anchor. They are reduced mainly in
paroxysmal nocturnal hemoglobinuria (PNH) and in other hematological disorders. However, there are very few reports in the literature concerning their expression in patients with acute
leukemias (AL). We studied the CD55 and CD59 expression in 88 newly diagnosed patients with AL [65 with acute non-
lymphoblastic leukemia (
ANLL) and 23 with
acute lymphoblastic leukemia (ALL)] using the sephacryl gel test, the Ham and
sucrose lysis tests and we compared the results with patients' clinical data and disease course. Eight patients with PNH were also studied as controls. Red cell populations deficient in both CD55 and CD59 were detected in 23% of
ANLL patients (especially of M(0), M(2) and M(6) FAB subtypes), 13% of ALL and in all PNH patients. CD55-deficient erythrocytes were found in 6
ANLL patients while the expression of CD59 was decreased in only 3 patients with
ANLL. No ALL patient had an isolated deficiency of these
antigens. There was no correlation between the existence of CD55 and/or
CD59 deficiency and the percentage of bone marrow infiltration, karyotype or response to treatment. However no patient with M(3), M(5),
M(7) subtype of
ANLL and mature B- or T-cell ALL showed a reduced expression of both
antigens. The deficient populations showed no alteration after
chemotherapy treatment or during disease course. This study provides evidence about the lower expression of CD55 and CD59 in some AL patients and the correlation with their clinical data. The possible mechanisms and the significance of this phenotype are discussed.